TGF-β knockout and dominant-negative receptor transgenic mice

Mineral and Electrolyte Metabolism

Volumn 24, Issue 2-3, 1998, Pages 161-167

  Letterio, John J ^a   Böttinger, Erwin P ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Development; Inflammation; Knockout; Malignancy; Mice; TGF ; Transgenic

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; GENE MUTATION; GENETIC MODEL; GENETIC RECOMBINATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; AUTOIMMUNITY; GROWTH; IMMUNITY; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MAMMALIA; MUS MUSCULUS;

EID: 0031908807     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057365     Document Type: Review

References (56)

1. Sporn MB: The importance of context in cytokine action. Kidney Int 1997;51:1352-1354.
2. Roberts AB, Sporn MB: The transforming growth factors-β; in Sporn MB, Roberts AB (eds): Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors. Berlin, Springer, 1990, pp 419-472.
3. Miller DA, Lee A, Matsui Y, Chen EY, Moses HL, Derynck R: Complementary DNA cloning of the murine transforming growth factor-beta 3 (TGF beta 3) precursor and the comparative expression of TGF beta 3 and TGF beta 1 messenger RNA in murine embryos and adult tis-sue. Mol Endocrinol 1989;3:1926-1934.
4. Thompson NL, Bazoberry F, Speier EH, Casscells W, Ferrans VJ, Flanders KC, Kondaiah P, Geiser AG, Sporn MB: Transforming growth factor beta-1 in acute myocardial infaction in rats. Growth Factors 1988;1:91-99.
5. Miller DA, Pelton RW, Derynck R, Moses HL: Transforming growth factor-beta. A family of growth regulatory peptides. Ann NY Acad Sci 1990;593;208-217.
6. Bonyadi M, Rusholme SA, Cousins FM, Su HC, Biron CA, Farrall M, Akhurst RJ: Mapping of a major genetic modifier of embryonic lethality in TGF beta 1 knockout mice. Nat Genet 1997;15:207-211.
7. Kulkarni AB, Ward JM, Yaswen L, Mackall CL, Bauer SR, Huh CG, Gress RE, Karlsson S: Transforming growth factor-beta I null mice. An animal model for inflammatory disorders. Am J Pathol 1995;146:264-275.
8. Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, Longenecker G, Mozes E, Karlsson S: Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 1996;87:1439-1445.
9. Letterio JJ, Roberts AB: Transforming growth factor-beta 1-deficient mice: Identification of isoform-specific activities in vivo. J Leukoc Biol 1996;59:769-774.
10. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB: Maternal rescue of transforming growth factor-beta 1 null mice. Science 1994;264:1936-1938.
11. Caver TE, O'Sullivan FX, Gold LI, Gresham HD: Intracellular demonstration of active TGF-beta 1 in B cells and plasma cells of autoimmune mice. IgG-bound TGFbeta1 suppresses neutrophil function and host defense against Staphylococcus aureus infection. J Clin Invest 1996;98:2496-2506.
12. Böttinger EP, Jakubczak JL, Roberts ISD, Mumy M, Hemmati P, Bagnall K, Merlino G, Wakefield LM: Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J 1997;16:2621-2633.
13. Wang XJ, Greenhalgh DA, Bickenbach JR, Jiang A, Bundman DS, Krieg T, Derynck R, Roop DR: Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proc Natl Acad Sci USA 1997;94:2386-2391.
14. Sanford LP, Ormsby I, Gittenberger-de Groot A, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T: TGF-β2 knockout mice have multiple developmental defects that are non-overlapping with other TGF-β knockout phenotypes. Development 1997;124:2659-2670.
15. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MW, Doetschman T: Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995;11:409-414.
16. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J: Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995;11:415-421.
17. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90: 770-774.
18. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-699.
19. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE: Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA 1993;90:4577-4581.
20. Gamble JR, Khew-Goodall Y, Vadas MA: Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol 1993;150:4494-4503.
21. Hines KL, Kulkarni AB, McCarthy JB, Tian H, Ward JM, Christ M, McCartney-Francis NL, Furcht LT, Karlsson S, Wahl SM: Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice. Proc Natl Acad Sci USA 1994;91:5187-5191.
22. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, Doetschman T: Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci USA 1995;92:12215-12219.
23. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE: Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol 1991;146: 3012-3017.
24. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ: Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991;88:2918-2921.
25. Racke MK, Cannella B, Albert P, Sporn M, Raine CS, McFarlin DE: Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int Immunol 1992;4:615-620.
26. Boivin GP, Ormsby I, Jones-Carson J, O'Toole BA, Doetschman T: Germ-free and barrierraised TGF beta 1-deficient mice have similar inflammatory lesions. Transgen Res 1997;6: 197-202.
27. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol 1995;155:3205-3212.
28. GeiserAG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB: Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: Aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci USA 1993;90:9944-9948.
29. Steinman L: Escape from 'horror autotoxicus': Pathogenesis and treatment of autoimmune disease. Cell 1995;80:7-10.
30. Scott B, Liblau R, Degermann S, Marconi LA, Ogata L, Caton AJ, McDevitt HO, Lo D: A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994;1:73-83.
31. Sobel RA, Colvin RB: The immunopathology of experimental allergic enecphalomyelitis (EAE). III. Differential in situ expression of strain 13 Ia on endothelial and inflammatory cells of (strain 2 × strain 13)F1 guinea pigs with EAE. J Immunol 1985;134:2333-2337.
32. Letterio JJ, Geiser AG, Kulkarni AB, Dang H, Kong L, Nakabayashi T, Mackall CL, Gress RE, Roberts AB: Autoimmunity associated with TGF-betal-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest 1996;98:2109-2119.
33. Steinberg AD: MRL-lpr/lpr disease: theories meet Fas. Semin Immunol 1994;6:55-69.
34. Lowrance JH, O'Sullivan FX, Caver TE, Waegell W, Gresham HD: Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med 1994; 180:1693-1703.
35. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ: Defective haemotopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995;121:1845-1854.
36. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB: Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest 1990;86:1976-1984.
37. Millan FA, Denhez F, Kondaiah P, Akhurst RJ: Embryonic gene expression patterns of TGF beta 1, beta 2 and beta 3 suggest different developmental functions in vivo. Development 1991;111:131-143.
38. Roberts AB, Sporn MB: Differential expression of the TGF-beta isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol Reprod Dev 1992;32:91-98.
39. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB: Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 1990;10:1492-1497.
40. Roberts AB, Sporn MB: Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993;8:1-9.
41. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
42. Oshima M, Oshima H, Taketo MM: TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 1996;179:297-302.
43. Brand T, MacLellan WR, Schneider MD: A dominant-negative receptor for type beta transforming growth factors created by deletion of the kinase domain. J Biol Chem 1993;268: 11500-11503.
44. Chen RH, Ebner R, Derynck R: Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science 1993;260:1335-1338.
45. Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson S, Yuspa SH: Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 1993;90:6076-6080.
46. Lee MS, Gu D, Feng L, Curriden S, Arnush M, Krahl T, Gurushanthaiah D, Wilson C, Loskutoff DL, Fox H, Sarvetnick N: Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-beta 1. Am J Pathol 1995;147:42-52.
47. Bascom CC, Wolfshohl JR, Coffey RJ Jr, Madisen L, Webb NR, Purchio AR, Derynck R, Moses HL: Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Mol Cell Biol 1989;9:5508-5515.
48. Markowitz SD, Roberts AB: Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 1996;1:93-102.
49. Gold LI, Korc M: Expression of transforming growth factor-β1, 2, and 3 mRNA and protein in human cancers. Dig Surg 1994;11:150-156.
50. Knaus PI, Lindemann D, DeCoteau JF, Perlman R, Yankelev H, Hille M, Kadin ME, Lodish HF: A dominant inhibitory mutant of the type II transforming growth factor β receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 1996;16:3480-3489.
51. Roberts AB: Transforming growth factor-beta: Activity and efficacy in animal models of wound healing. Wound Rep Reg 1995;3:408-418.
52. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996;93: 2909-2914.
53. Wojtowicz-Praga S, Verma UM, Wakefield L, Esteban JM, Hartmann D, Mazumder A: Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Emphasis Tumor Immunol 1996;19:169-175.
54. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT: Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: Implications for a possible role of tumor cell/host TGF-beta interations in human breast cancer progression. J Clin Invest 1993;92:2569-2576.
55. Hoefer M, Anderer FA: Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol Immunother 1995;41:302-308.
56. Qin L, Ding Y, Bromberg JS: Gene transfer of transforming growth factor-beta 1 prolongs murine cardiac allograft survival by inhibiting cell-mediated immunity. Hum Gene Ther 1996;7:1981-1988.